Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CNTA Stock Forecast 2026-2027
$40.50
Current Price
$6.27B
Market Cap
Buy 2
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to CNTA Price Targets
+11.1%
To High Target of $45.00
-3.7%
To Median Target of $39.00
-6.2%
To Low Target of $38.00
CNTA Price Momentum
0.0%
1 Week Change
+1.6%
1 Month Change
+153.8%
1 Year Change
+61.9%
Year-to-Date Change
-0.1%
From 52W High of $40.56
+216.9%
From 52W Low of $12.78
📊 TOP ANALYST CALLS
Did CNTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Centessa is one of their latest high-conviction picks.
Latest CNTA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CNTA has a neutral consensus with a median price target of $39.00 (ranging from $38.00 to $45.00). The overall analyst rating is Buy (6.8/10). Currently trading at $40.50, the median forecast implies a -3.7% downside. This outlook is supported by 2 Buy, 5 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CNTA Analyst Ratings
2
Buy
5
Hold
0
Sell
CNTA Price Target Range
Low
$38.00
Average
$39.00
High
$45.00
Current: $40.50
Latest CNTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CNTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 20, 2026 | Wells Fargo | Benjamin Burnett | Equal-Weight | Downgrade | $42.00 |
| Apr 2, 2026 | Guggenheim | Neutral | Downgrade | $N/A | |
| Apr 1, 2026 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Mar 31, 2026 | Wolfe Research | Peer Perform | Downgrade | $N/A | |
| Mar 31, 2026 | Needham | Hold | Downgrade | $N/A | |
| Feb 24, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Jan 29, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jan 2, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 10, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Dec 1, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Nov 18, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Nov 13, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Nov 7, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 28, 2025 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Oct 6, 2025 | Guggenheim | Buy | Reiterates | $N/A | |
| Sep 3, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Aug 12, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jul 30, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jul 21, 2025 | Truist Securities | Buy | Initiates | $N/A |
Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) Competitors
The following stocks are similar to Centessa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) Financial Data
Centessa Pharmaceuticals plc American Depositary Receipt has a market capitalization of $6.27B with a P/E ratio of -27.7x. The company generates $15.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -1,228.4% and return on equity of -57.4%.
Valuation Metrics
Market Cap
$6.27B
Enterprise Value
$6.11B
P/E Ratio
-27.7x
PEG Ratio
-0.2x
Price/Sales
417.8x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-1,228.4%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
9.5x
Debt/Equity
24.3x
ROE
-57.4%
ROA
-27.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) Business Model
About Centessa Pharmaceuticals plc American Depositary Receipt
What They Do
Develops innovative medicines for unmet medical needs.
Business Model
Centessa Pharmaceuticals operates as a clinical-stage pharmaceutical company that generates revenue through the research, development, and potential commercialization of novel therapeutics. Its business model is centered around a diverse and innovative pipeline that targets various therapeutic areas, allowing the company to address high unmet medical needs and capitalize on advancements in drug development.
Additional Information
Founded in 2020 and headquartered in Altrincham, UK, Centessa Pharmaceuticals focuses on delivering transformational therapies with an integrated platform. The company has multiple programs in different stages of development, including recent FDA clearance for Phase 1 studies of ORX142, showcasing its commitment to advancing novel treatments for complex diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
129
CEO
Dr. Mario Alberto Accardi Ph.D.
Country
United Kingdom
IPO Year
2021
Website
centessa.comCentessa Pharmaceuticals plc American Depositary Receipt (CNTA) Latest News & Analysis
Latest News
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
24 days ago
Quick Summary
Centessa Pharmaceuticals has received High Court approval for its acquisition by Eli Lilly at $38 per share, plus a potential $9 in milestones, totaling about $7.8 billion.
Why It Matters
The approval of Eli Lilly's acquisition of Centessa Pharmaceuticals at $38 per share signals confidence in Centessa's pipeline, potentially impacting stock valuations and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Actinium Pharmaceuticals appointed Dr. Steffen Heeger as Chief Medical Officer, leveraging his oncology expertise to advance Actimab-A, ATNM-400, and Iomab-A towards key data readouts in 2H:2026.
Why It Matters
Dr. Heeger's appointment enhances Actinium's leadership in targeted radiotherapies, potentially accelerating the development of key drugs and improving investor confidence ahead of critical data releases.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Centessa Pharmaceuticals is being investigated regarding its proposed sale to Eli Lilly for $38.00 per share plus contingent value rights.
Why It Matters
The investigation into Centessa Pharmaceuticals' sale to Eli Lilly could impact share prices and investor sentiment, especially regarding the deal's terms and potential legal challenges.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ademi LLP is investigating Centessa (NASDAQ: CNTA) for potential fiduciary duty breaches related to its transaction with Lilly.
Why It Matters
The investigation into Centessa could signal potential legal risks and corporate governance issues, which may impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Eli Lilly announced its acquisition of Centessa Pharmaceuticals for approximately $6.3 billion to enhance its portfolio in sleep-wake disorder treatments.
Why It Matters
Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals enhances its portfolio in sleep-wake disorder treatments, potentially driving future revenue growth and market competitiveness.
Source: Reuters
Market Sentiment:
Positive
Why Centessa Stock Soared Today
3 months ago
Quick Summary
Centessa has a strong pipeline in sleep medicine, with its experimental therapies showing potential for significant market impact.
Why It Matters
Centessa's promising sleep medicine pipeline and potential blockbuster therapies could lead to significant revenue growth, influencing stock performance and attracting investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About CNTA Stock
What is Centessa Pharmaceuticals plc American Depositary Receipt's (CNTA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Centessa Pharmaceuticals plc American Depositary Receipt (CNTA) has a median price target of $39.00. The highest price target is $45.00 and the lowest is $38.00.
Is CNTA stock a good investment in 2027?
According to current analyst ratings, CNTA has 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $40.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CNTA stock?
Wall Street analysts predict CNTA stock could reach $39.00 in the next 12 months. This represents a -3.7% decrease from the current price of $40.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Centessa Pharmaceuticals plc American Depositary Receipt's business model?
Centessa Pharmaceuticals operates as a clinical-stage pharmaceutical company that generates revenue through the research, development, and potential commercialization of novel therapeutics. Its business model is centered around a diverse and innovative pipeline that targets various therapeutic areas, allowing the company to address high unmet medical needs and capitalize on advancements in drug development.
What is the highest forecasted price for CNTA Centessa Pharmaceuticals plc American Depositary Receipt?
The highest price target for CNTA is $45.00 from at , which represents a 11.1% increase from the current price of $40.50.
What is the lowest forecasted price for CNTA Centessa Pharmaceuticals plc American Depositary Receipt?
The lowest price target for CNTA is $38.00 from at , which represents a -6.2% decrease from the current price of $40.50.
What is the overall CNTA consensus from analysts for Centessa Pharmaceuticals plc American Depositary Receipt?
The overall analyst consensus for CNTA is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $39.00.
How accurate are CNTA stock price projections?
Stock price projections, including those for Centessa Pharmaceuticals plc American Depositary Receipt, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 4:37 AM UTC